News items related to: Sofosbuvir

Posted August 7, 2019 by ITPC

Adapted from a story first published by GTPI. Compulsory licensing is a vital public policy tool to combat the high...

Read more about Brazilian Health Minister’s speech on compulsory licenses exposes a disconnect with the world

Posted July 28, 2019 by ITPC

Today, 28 July, is World Hepatitis Day 2019. Since the day was marked in 2018, another 1.4 million people have...

Read more about World Hepatitis Day 2019: 1.4 million lives lost since last year

Posted July 1, 2019 by ITPC

Our partner in Argentina, Fundación GEP (FGEP), has filed an opposition against Gilead’s patent application for the combination, sofosbuvir +...

Read more about Fundación GEP, Argentina, files patent opposition on Hepatitis C treatment

Posted August 23, 2018 by ITPC

Activists gathered at the Brazilian Patent Office (INPI) in Rio de Janeiro this week, and Gilead’s office in São Paulo....

Read more about The people against Gilead. Activists protest at the Brazilian patent office, calling for Gilead’s last sofosbuvir patent application to be rejected

Posted May 11, 2018 by ITPC

Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position...

Read more about Collective efforts by civil society groups bar the way to Hepatitis C patents

Posted May 5, 2018 by ITPC

Civil society plays an instrumental role in actively defending access to affordable to medicines, making use of TRIPS flexibilities, and...

Read more about Civil society key in TRIPS flexibility implementation

Posted May 4, 2018 by ITPC

Rejected! That was the decision issued by Brazil’s National Institute of Industrial Property (INPI) over one of Gilead’s patent applications...

Read more about Gilead’s patent application on sofosbuvir rejected in Brazil

Posted February 23, 2018 by ITPC

Marrakech was home to the signing of the TRIPS Agreement in 1995, an agreement that has been exploited by pharmaceutical...

Read more about Fixing the broken patent system: From Marrakech and back again

Posted January 30, 2018 by ITPC

[View the story “Pathways to Access! #GSIPA2M (15-17 Jan 2018)” on Storify] SaveSave

Read more about Storify: Pathways to Access #GSIPA2M

Posted January 18, 2018 by ITPC

Malaysia’s “historic decision” to issue a compulsory license on Hep C medicine, sofosbuvir, stands up to Big Pharma, and will mean...

Read more about GSIPA2M: Malaysia Ministry of Health 2018 winner of the Leadership Award on Intellectual Property and Access to Medicines